Form 4: Dexcom Executive Adjusts Holdings

Dexcom Inc. EVP and CFO Jereme M. Sylvain reported a transaction involving the withholding of shares for tax obligations and disclosed beneficial ownership details.

Summary

• Jereme M. Sylvain, EVP and Chief Financial Officer of Dexcom Inc., reported a transaction on May 22, 2026.
• The transaction involved 1,451 shares of common stock, acquired at a price of $71.90, which were withheld by the Issuer to cover tax withholding and remittance obligations.
• This action does not represent a sale by the Reporting Person.
• Following this transaction, Sylvain beneficially owns 151,841 shares of common stock directly.
• This total includes 89,944 unvested restricted stock units (RSUs) granted on various dates between March 8, 2024, and March 8, 2026, with vesting schedules extending through March 8, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard administrative transaction related to executive compensation and does not indicate a change in the executive's investment strategy or the company's performance.

Positives

• The transaction is a standard procedure for covering tax liabilities on equity awards, indicating normal compensation and vesting processes.
• The reporting person continues to hold a significant number of shares (151,841), suggesting continued commitment to the company.

Negatives

• The withholding of shares for tax purposes, while standard, reduces the immediate number of shares available to the reporting person.

Future Outlook

The filing details the vesting schedules of restricted stock units, indicating future potential equity awards to the reporting person over the next several years.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, providing transparency into insider holdings and transactions. This filing for Dexcom Inc. is typical for a company with a robust equity compensation program.

Stakeholder Impact

• Shareholders: Increased transparency regarding executive holdings and compensation-related transactions.

Next Steps

• Continued vesting of restricted stock units according to the disclosed schedules through March 8, 2029.

Key Dates

Keywords

Dexcom Inc., DXCM, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSUs, Tax Withholding, Executive Compensation, Jereme M. Sylvain